{"id":"W1423581981","doi":"10.1016/j.jacl.2015.08.006","title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","year":2015,"lang":"en","type":"article","venue":"Journal of clinical lipidology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":467,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Amarin Corporation; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; CSL Behring; Danone; Amarin Pharma; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Esperion Therapeutics; GlaxoSmithKline","keywords":"Medicine; Alirocumab; Ezetimibe; Statin; Internal medicine; Pharmacology; Cholesterol; Total cholesterol","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01559552,0.0001850434,0.002695607,0.0001263363,0.00003022763,0.000008137894,0.0001619346,0.0001865079,0.00003145831],"category_scores_gemma":[0.009770103,0.00009088758,0.0004250585,0.0001346132,0.0004662171,0.00007282563,0.00005838927,0.0009890324,0.000001544719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005382295,"about_ca_system_score_gemma":0.000709983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001381907,"about_ca_topic_score_gemma":0.00005648033,"domain_scores_codex":[0.992326,0.003659509,0.002753428,0.0002348387,0.0007700412,0.0002561812],"domain_scores_gemma":[0.992358,0.004532789,0.001724135,0.0003345301,0.0007263237,0.0003242103],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9638104,0.001283429,0.002498748,0.00004917837,0.0007660867,0.00002637156,0.001331843,0.00004982945,7.29801e-7,0.0002073355,0.0003968342,0.02957916],"study_design_scores_gemma":[0.9595674,0.01599993,0.01823014,0.0002880004,0.000445427,0.0000755224,0.0003533769,0.0001076429,0.000007681995,0.0007316166,0.004090357,0.0001029019],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890851,0.0007572485,0.001202347,0.005302425,0.001399122,0.00193781,0.000008838052,0.000005018603,0.0003020854],"genre_scores_gemma":[0.9905579,0.002095662,0.003992975,0.0009518735,0.002319372,0.00002045875,0.000006497467,0.00002483003,0.00003044453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02947626,"threshold_uncertainty_score":0.998571,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0757458802216295,"score_gpt":0.3849540900123038,"score_spread":0.3092082097906743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}